Severe hepatic encephalopathy: an osmotic shift in management

Severe hepatic encephalopathy: an osmotic shift in management

G. Bryan Young

Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada

Correspondence to: G. Bryan Young. 1800-8th Street East, Owen Sound, Ontario, Canada. Email:

Provenance: This is an invited Editorial commissioned by the Executive Editor Dr. Zhongheng Zhang (Department of Emergency Medicine, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China).

Comment on: Liotta EM, Romanova AL, Lizza BD, et al. Osmotic Shifts, Cerebral Edema, and Neurologic Deterioration in Severe Hepatic Encephalopathy. Crit Care Med 2018;46:280-9.

Received: 09 October 2018; Accepted: 10 October 2018; Published: 02 November 2018.

doi: 10.21037/jeccm.2018.10.02

Acute or acute-on-chronic, severe hepatic failure is associated with high mortality that increases with severity of encephalopathy (1). Death and morbidity from neurological causes is usually due to severe cerebral edema, which can progress to herniation, a late complication (2).

An increase in serum ammonia is central to our understanding of acute hepatic encephalopathy. The brain lacks a urea cycle for detoxication of ammonia (3,4). The conversion of urea into glutamine is a glial function, but the glial internalization of urea, glutamine and other compounds, some toxic, is thought to cause glial swelling and cerebral edema. Cerebral edema is likely to occur with serum ammonia concentrations above 200 mols/L (5). Careful clinical monitoring for behavioural and cognitive changes is important to prompt intervention to prevent progression to brain swelling. Methods to reduce ammonia toxicity include: use of enteral lactulose and intravenous L-ornithine-L-aspartate (6); enteral rifampin and probiotics are useful in patients with cirrhosis (7,8).

The mechanism for cerebral edema is likely multifactorial. The edema is both cytotoxic (mentioned above) and vasogenic (due to alterations in the blood-brain barrier), but the cytotoxic mechanism, related to astrocytic swelling predominates (9).

Once cerebral edema occurs, measures are needed to monitor and reduce brain swelling. Intracranial pressure monitoring is recommended, but, because of the frequent association of coagulopathy in these patients, is seldom done. Serial CT head scans is one method of monitoring such patients. Liotta et al. (10) in this issue followed the changes intracranial CSF volume as a method of detecting and following cerebral edema in patients with severe hepatic encephalopathy. Furthermore, they showed a correlation of decline in serum osmolality with worsening cerebral edema. Changes in serum sodium concentration did not correlate as well, constituting an osmolar gap. This is an important and overlooked finding and represents an important means of following and preventing worsening of cerebral edema by preventing osmotic shifts. Thus, treating plasma osmolarity is key. This is usually done, in extreme cases treated in ICUs, by using mannitol or hypertonic saline. Measures to reduce serum ammonia are still worth attempting. The combination of such strategies can buy time to allow hepatic function to recover or for liver transplantation.




Conflicts of Interest: The author has no conflicts of interest to declare.


  1. Fichet J, Mercier E, Genée O, et al. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care 2009;24:364-70. [Crossref] [PubMed]
  2. Kodali S, McGuire BM. Diagnosis and Management of Hepatic Encephalopathy in Fulminant Hepatic Failure. Clin Liver Dis 2015;19:565-76. [Crossref] [PubMed]
  3. Butterworth RF. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. J Clin Exp Hepatol 2015;5:S96-103. [Crossref] [PubMed]
  4. Scott TR, Kronsten VT, Hughes RD, et al. Pathophysiology of cerebral oedema in acute liver failure. World J Gastroenterol 2013;19:9240-55. [Crossref] [PubMed]
  5. Ge PS, Runyon BA. Serum ammonia level for the evaluation of hepatic encephalopathy. JAMA 2014;312:643-4. [Crossref] [PubMed]
  6. American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014;61:642-59. [Crossref] [PubMed]
  7. Bass NM, Mullen KD, Sanyal A. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-81. [Crossref] [PubMed]
  8. McGee RG, Bakens A, Wiley K, et al. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011. [PubMed]
  9. Wijdicks EF. Hepatic Encephalopathy. N Engl J Med 2016;375:1660-70. [Crossref] [PubMed]
  10. Liotta EM, Ramanova ML, Lizza BD, et al. Osmotic shits, cerebral edema and neurologic deterioration in severe hepatic encephalopathy. Crit Care Med 2018;46:280-9. [Crossref] [PubMed]
doi: 10.21037/jeccm.2018.10.02
Cite this article as: Young GB. Severe hepatic encephalopathy: an osmotic shift in management. J Emerg Crit Care Med 2018;2:87.